|
US3536809A
(en)
|
1969-02-17 |
1970-10-27 |
Alza Corp |
Medication method
|
|
US3598123A
(en)
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
|
US3916899A
(en)
|
1973-04-25 |
1975-11-04 |
Alza Corp |
Osmotic dispensing device with maximum and minimum sizes for the passageway
|
|
US4008719A
(en)
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
|
US5001116A
(en)
|
1982-12-20 |
1991-03-19 |
The Children's Medical Center Corporation |
Inhibition of angiogenesis
|
|
US4994443A
(en)
|
1982-12-20 |
1991-02-19 |
The Children's Medical Center Corporation |
Inhibition of angiogenesis
|
|
IE58110B1
(en)
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
US5391485A
(en)
|
1985-08-06 |
1995-02-21 |
Immunex Corporation |
DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
|
|
US4810643A
(en)
|
1985-08-23 |
1989-03-07 |
Kirin- Amgen Inc. |
Production of pluripotent granulocyte colony-stimulating factor
|
|
JPS63500636A
(ja)
|
1985-08-23 |
1988-03-10 |
麒麟麦酒株式会社 |
多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
|
|
US5073543A
(en)
|
1988-07-21 |
1991-12-17 |
G. D. Searle & Co. |
Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
|
|
IT1229203B
(it)
|
1989-03-22 |
1991-07-25 |
Bioresearch Spa |
Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
|
|
US5120548A
(en)
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
|
KR0166088B1
(ko)
|
1990-01-23 |
1999-01-15 |
. |
수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
|
|
US5733566A
(en)
|
1990-05-15 |
1998-03-31 |
Alkermes Controlled Therapeutics Inc. Ii |
Controlled release of antiparasitic agents in animals
|
|
US5580578A
(en)
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
|
EP0631635B1
(en)
|
1992-03-04 |
2001-09-12 |
The Regents Of The University Of California |
Comparative genomic hybridization (cgh)
|
|
US5441050A
(en)
|
1992-12-18 |
1995-08-15 |
Neoprobe Corporation |
Radiation responsive surgical instrument
|
|
US5591767A
(en)
|
1993-01-25 |
1997-01-07 |
Pharmetrix Corporation |
Liquid reservoir transdermal patch for the administration of ketorolac
|
|
US6114355A
(en)
|
1993-03-01 |
2000-09-05 |
D'amato; Robert |
Methods and compositions for inhibition of angiogenesis
|
|
US5629327A
(en)
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
|
US8143283B1
(en)
|
1993-03-01 |
2012-03-27 |
The Children's Medical Center Corporation |
Methods for treating blood-born tumors with thalidomide
|
|
US5698579A
(en)
|
1993-07-02 |
1997-12-16 |
Celgene Corporation |
Cyclic amides
|
|
IT1270594B
(it)
|
1994-07-07 |
1997-05-07 |
Recordati Chem Pharm |
Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
|
|
US5573758A
(en)
|
1995-04-28 |
1996-11-12 |
Allergan |
Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
|
|
US6333307B1
(en)
|
1996-07-12 |
2001-12-25 |
Mcgill University |
Compounds and method for modulating neurite outgrowth
|
|
US6207639B1
(en)
|
1996-07-12 |
2001-03-27 |
Mcgill University |
Compounds and methods for modulating neurite outgrowth
|
|
DE69739802D1
(de)
|
1996-07-24 |
2010-04-22 |
Celgene Corp |
Substituierte 2-(2,6-Dioxopiperidine-3-yl)-phthalimide -1-oxoisoindoline und Verfahren zur Reduzierung des TNF-alpha Spiegels
|
|
HU228769B1
(en)
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
|
US5635517B1
(en)
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
|
US5798368A
(en)
|
1996-08-22 |
1998-08-25 |
Celgene Corporation |
Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
|
|
US6281230B1
(en)
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
|
ES2315435T3
(es)
|
1996-08-12 |
2009-04-01 |
Celgene Corporation |
Nuevos agentes inmunoterapeuticos y su uso para la reduccion de los niveles de citoquinas.
|
|
US5955476A
(en)
|
1997-11-18 |
1999-09-21 |
Celgene Corporation |
Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
|
|
US5874448A
(en)
|
1997-11-18 |
1999-02-23 |
Celgene Corporation |
Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
|
|
US6221585B1
(en)
|
1998-01-15 |
2001-04-24 |
Valigen, Inc. |
Method for identifying genes underlying defined phenotypes
|
|
ES2243052T3
(es)
|
1998-03-16 |
2005-11-16 |
Celgene Corporation |
Derivados de la 2- (2,6-dioxopiperidin-3-il) isoindolina, su preparacion y su empleo como inhibidores de las citocinas inflamatorias.
|
|
US6472367B1
(en)
|
1998-05-05 |
2002-10-29 |
Adherex Technologies, Inc. |
Compounds and methods for modulating OB-cadherin mediated cell adhesion
|
|
AU759144B2
(en)
|
1998-05-05 |
2003-04-03 |
Adherex Technologies Inc. |
Compounds and methods for modulating nonclassical cadherin-mediated functions
|
|
US6680175B2
(en)
|
1998-05-05 |
2004-01-20 |
Adherex Technologies, Inc. |
Methods for diagnosing and evaluating cancer
|
|
US6277824B1
(en)
|
1998-07-10 |
2001-08-21 |
Adherex Technologies |
Compounds and methods for modulating adhesion molecule function
|
|
US6322962B1
(en)
|
1998-08-14 |
2001-11-27 |
Board Of Regents, The University Of Texas System |
Sterol-regulated Site-1 protease and assays of modulators thereof
|
|
US6927024B2
(en)
|
1998-11-30 |
2005-08-09 |
Genentech, Inc. |
PCR assay
|
|
TR200102688T2
(tr)
|
1999-03-18 |
2002-01-21 |
Celgene Corporation |
İkameli 1-okso ve 1,3-dioksoizoindolinler ve enflamatuar sitokin seviyelerinin azaltılması için farmasötik bileşimlerde kullanımları.
|
|
WO2001042507A1
(en)
|
1999-12-09 |
2001-06-14 |
Advanced Research & Technology Institute |
Fluorescent in situ rt-pcr
|
|
US6458810B1
(en)
|
2000-11-14 |
2002-10-01 |
George Muller |
Pharmaceutically active isoindoline derivatives
|
|
US20030045552A1
(en)
|
2000-12-27 |
2003-03-06 |
Robarge Michael J. |
Isoindole-imide compounds, compositions, and uses thereof
|
|
US7091353B2
(en)
|
2000-12-27 |
2006-08-15 |
Celgene Corporation |
Isoindole-imide compounds, compositions, and uses thereof
|
|
CA2439402A1
(en)
|
2001-03-02 |
2002-09-12 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Pcr method
|
|
US7981863B2
(en)
|
2001-09-19 |
2011-07-19 |
Neuronova Ab |
Treatment of Parkinson's disease with PDGF
|
|
US20030194708A1
(en)
|
2002-04-10 |
2003-10-16 |
Minke Binnerts |
Human homolog of crossveinless materials and methods
|
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
|
WO2004004652A2
(en)
*
|
2002-07-08 |
2004-01-15 |
Merck & Co., Inc. |
Mitotic kinesin binding site
|
|
US7189740B2
(en)
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
|
US7122799B2
(en)
|
2003-12-18 |
2006-10-17 |
Palo Alto Research Center Incorporated |
LED or laser enabled real-time PCR system and spectrophotometer
|
|
US7244759B2
(en)
|
2004-07-28 |
2007-07-17 |
Celgene Corporation |
Isoindoline compounds and methods of making and using the same
|
|
US20080051379A1
(en)
|
2004-12-01 |
2008-02-28 |
Trustees Of Boston University |
Compositions and Methods for the Treatment of Peripheral B-Cell Neoplasms
|
|
CN101111234A
(zh)
|
2004-12-01 |
2008-01-23 |
细胞基因公司 |
包含免疫调节化合物的组合物及其治疗免疫缺陷疾病的用途
|
|
AR052196A1
(es)
|
2005-01-25 |
2007-03-07 |
Celgene Corp |
Metodos y composiciones que utilizan 4-amino-2-(3-metil-2,6- dioxopiperidin-3-il)-isoindol-1,3-diona
|
|
US7504225B2
(en)
|
2005-05-12 |
2009-03-17 |
Applied Genomics, Inc. |
Reagents and methods for use in cancer diagnosis, classification and therapy
|
|
US7776551B2
(en)
|
2005-07-12 |
2010-08-17 |
Ramot At Tel Aviv University Ltd. |
Methods and kits for diagnosing and treating mental retardation
|
|
BRPI0614995A2
(pt)
|
2005-08-31 |
2010-01-12 |
Celgene Corp |
composto ou um sal, solvato ou estereoisemero farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de uma quantidade terapêutica ou profilaticamente eficaz de um composto ou um sal, solvato ou estereoisemero farmaceuticamente aceitável do mesmo, e, forma de dosagem unitária única
|
|
US8445198B2
(en)
|
2005-12-01 |
2013-05-21 |
Medical Prognosis Institute |
Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
|
|
WO2007067500A2
(en)
|
2005-12-05 |
2007-06-14 |
Genomic Health, Inc. |
Predictors of patient response to treatment with egfr inhibitors
|
|
US7892740B2
(en)
|
2006-01-19 |
2011-02-22 |
The University Of Chicago |
Prognosis and therapy predictive markers and methods of use
|
|
CA2644716A1
(en)
|
2006-03-13 |
2007-09-27 |
Merck & Co., Inc. |
Ophthalmic compositions for treating ocular hypertension
|
|
WO2008005281A2
(en)
|
2006-06-30 |
2008-01-10 |
Rosetta Inpharmatics Llc |
Genes associated with chemotherapy response and uses thereof
|
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
|
LT2420498T
(lt)
|
2006-09-26 |
2017-10-25 |
Celgene Corporation |
5-pakeistieji chinazolinono dariniai, kaip priešvėžiniai agentai
|
|
US20080280779A1
(en)
|
2006-09-26 |
2008-11-13 |
Shaughnessy Jr John D |
Gene expression profiling based identification of genomic signatures of multiple myeloma and uses thereof
|
|
US20090075281A1
(en)
|
2007-07-10 |
2009-03-19 |
Regents Of The University Of California |
Mtbe genes
|
|
US20090148853A1
(en)
|
2007-12-07 |
2009-06-11 |
Schafer Peter H |
Biomarkers for predicting the sensitivity of cells to immunomodulatory compounds during treatment of non-hodgkin's lymphoma
|
|
US20100021437A1
(en)
|
2008-04-07 |
2010-01-28 |
The McLean Hospital Corporation Whitehead Institute for Biomedical Research |
Neural stem cells derived from induced pluripotent stem cells
|
|
CA2725551C
(en)
|
2008-05-26 |
2017-06-06 |
Yeda Research And Development Co. Ltd. |
Methods of treating cancer of the central nervous system
|
|
WO2010017515A2
(en)
|
2008-08-08 |
2010-02-11 |
Integrated Diagnostics Inc. |
Breast cancer specific markers and methods of use
|
|
AU2010236606A1
(en)
|
2009-04-14 |
2011-11-03 |
Merck Sharp & Dohme Corp. |
Interferon-alfa sensitivity biomarkers
|
|
EP2436387B1
(en)
|
2009-05-25 |
2018-07-25 |
Celgene Corporation |
Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex
|
|
WO2010141724A2
(en)
|
2009-06-03 |
2010-12-09 |
Dicerna Pharmaceuticals, Inc. |
Peptide dicer substrate agents and methods for their specific inhibition of gene expression
|
|
SG179021A1
(en)
|
2009-09-15 |
2012-04-27 |
Reactive Surface Ltd |
Anti-fouling paints and coatings
|
|
JP5660578B2
(ja)
*
|
2009-10-20 |
2015-01-28 |
国立大学法人東京工業大学 |
サリドマイド標的因子を利用したスクリーニング方法
|
|
PL2536706T3
(pl)
|
2010-02-11 |
2017-10-31 |
Celgene Corp |
Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
|
|
EP2544687A1
(en)
|
2010-03-12 |
2013-01-16 |
Celgene Corporation |
Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor
|
|
MY166040A
(en)
|
2010-09-15 |
2018-05-21 |
Almac Diagnostics Ltd |
Molecular diagnostic test for cancer
|
|
WO2012125405A2
(en)
|
2011-03-11 |
2012-09-20 |
Mayo Foundation For Medical Education And Research |
Methods and materials for assessing responsiveness to lenalidomide, thalidomide, and/or other thalidomide analogs
|
|
PT2683384E
(pt)
|
2011-03-11 |
2016-03-11 |
Celgene Corp |
Métodos de tratamento de cancro utilizando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona
|
|
EA026100B1
(ru)
|
2011-03-11 |
2017-03-31 |
Селджин Корпорейшн |
Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2,6-диона и их фармацевтические композиции и применение
|
|
MX353482B
(es)
|
2011-04-29 |
2018-01-16 |
Celgene Corp |
Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
|
|
US20130042333A1
(en)
|
2011-05-06 |
2013-02-14 |
Jean-Gabriel JUDDE |
Markers for cancer prognosis and therapy and methods of use
|
|
CA3136093C
(en)
*
|
2012-06-29 |
2025-07-08 |
Celgene Corporation |
METHODS FOR DETERMINING THE EFFICACY OF A DRUG USING PROTEINS ASSOCIATED WITH CEREBLON
|
|
JP6347782B2
(ja)
|
2012-08-09 |
2018-06-27 |
セルジーン コーポレイション |
３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンを使用する癌の治療方法
|
|
WO2014028445A2
(en)
|
2012-08-14 |
2014-02-20 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
|
CA2884103A1
(en)
|
2012-09-10 |
2014-03-13 |
Celgene Corporation |
Methods for the treatment of locally advanced breast cancer
|
|
WO2014204872A2
(en)
|
2013-06-14 |
2014-12-24 |
Complexa, Inc. |
Composition and method for inhibition of pkng from mycobacterium tuberculosis
|
|
WO2015077058A2
(en)
|
2013-11-08 |
2015-05-28 |
The Broad Institute, Inc. |
Compositions and methods for selecting a treatment for b-cell neoplasias
|
|
BR112016012795A2
(pt)
|
2013-12-06 |
2017-08-08 |
Celgene Corp |
Métodos para a determinação da eficácia do fármaco para o tratamento de linfoma difuso de grandes células b, mieloma múltiplo e cânceres mieloides
|
|
WO2015200795A1
(en)
|
2014-06-27 |
2015-12-30 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases
|
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
US9713375B1
(en)
|
2015-02-26 |
2017-07-25 |
Brett Einar Rahm |
Collapsible portable table
|
|
US10830762B2
(en)
|
2015-12-28 |
2020-11-10 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
|